Idoxifene - patents, research & applications

18,892Patents

62Research papers

1,602Patents - last 3 years

0Papers - last 3 years

Who owns the IP

The organizations most actively patenting around this compound, ranked by referenced patent volume.

#	Assignee	Patents
1	Merck Sharp & Dohme LLC	1,469
2	Celgene Corp	838
3	Merck Patent GmbH	744
4	Merck and Co Inc	580
5	Genentech Inc	445

6	Pharmacyclics LLC	371
7	Bristol Myers Squibb Co	353
8	AstraZeneca AB	339
9	F Hoffmann La Roche AG	310
10	Organon Pharma UK Ltd	288

Explore the full landscape

This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.

Visit Cypris

Where innovation is concentrated

Patent classifications ranked by volume reveal the technical domains with the most active filing.

#	Code	Area	Patents
1	`A61P`	Therapeutic activity (drug indications)	16,943
2	`A61K`	Medicinal preparations	13,908
3	`C07D`	Heterocyclic compounds	9,982
4	`C07K`	Peptides	3,851
5	`C12N`	Microorganisms, enzymes	1,480

6	`G01N`	Investigating / analysing materials	1,451
7	`Y02A`	Climate change adaptation	1,270
8	`C07C`	Acyclic and carbocyclic compounds	1,206
9	`C12Q`	Measuring/testing involving enzymes	740
10	`C07F`	Organometallic compounds	699

AI mapped opportunity space

This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.

See Cypris in action

Most-cited patents

Patents ranked by forward citations reveal the foundational inventions the field continues to build on.

Title	Year	Assignee
Method for synthesizing midbody of idoxifene	2026	ASTATECH (CHENGDU) BIOPHARMACEUTICAL CORP.
Compositions of (Z) -idoxifene and methods of enriching same	2024	Atosa therapeutics
THERAPEUTIC AGENTS BASED ON IDOXIFENO, USEFUL IN THE TREATMENT OF OSTEOPOROSIS	2000	SMITHKLINE BEECHAM CORPORATION
METHOD OF TREATING POST MENOPAUSAL DISEASES, INCLUDING OSTEOPOROSIS USING IDOXIFENE DERIVATIVES	2000	SMITHKLINE BEECHAM CORPORATION
Route B process for idoxifene	1999	SMITHKLINE BEECHAM PLC.

Where research is gaining momentum

Research themes ranked by publication activity show where scientific interest is accelerating around this compound.

#	Research topic	Papers
1	Estrogen and related hormone effects	1
2	Genomics, phytochemicals, and oxidative stress	1
3	Microtubule and mitosis dynamics	1

Who's driving the science

The most-published authors working with this compound, alongside their primary affiliations.

#	Author	Affiliation	Papers
1	Michael Jarman	Institute of Cancer Research	13
2	Mitch Dowsett	Royal Marsden Hospital	5
3	R. Charles Coombes	Charing Cross Hospital	5
4	Ben P. Haynes	The Honourable Society of Lincoln's Inn	4
5	Brian MacDonald	Vanderbilt University Medical Center	4

6	Eliot H. Ohlstein	New Frontier	4
7	Ian R. Hardcastle	Institute of Cancer Research	4
8	Jack D. Henion	Cornell University	4
9	Maxine Gowen	New Frontier	4
10	V. Craig Jordan	Robert H. Lurie Comprehensive Cancer Center of Northwestern University	4

Research leaders

This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.

See Cypris in action

The literature that defines it

The most-cited papers anchoring the scientific record for this compound.

Title	Year	Cited by	Topic
An assessment of the value of ultrasonographic screening for endometrial disease in postmenopausal women without symptoms	2001	100	Endometrial and Cervical Cancer Treatments
Bioanalytical High-Throughput Selected Reaction Monitoring-LC/MS Determination of Selected Estrogen Receptor Modulators in Human Plasma: 2000 Samples/Day	2000	97	Advanced Proteomics Techniques and Applications
High-resolution MRI and micro-FE for the evaluation of changes in bone mechanical properties during longitudinal clinical trials: application to calcaneal bone in postmenopausal women after one year of idoxifene treatment	2002	88	Bone health and osteoporosis research
Idoxifene: A Novel Selective Estrogen Receptor Modulator Prevents Bone Loss and Lowers Cholesterol Levels in Ovariectomized Rats and Decreases Uterine Weight in Intact Rats	1998	88	Menopause: Health Impacts and Treatments
Atmospheric pressure photoionization liquid chromatographic–mass spectrometric determination of idoxifene and its metabolites in human plasma	2002	85	Mass Spectrometry Techniques and Applications

Frequently asked questions

Common questions about this compound's patent and research landscape, answered from the underlying data.

What is the molecular composition and weight of Idoxifene?

Idoxifene has the molecular formula C28H30INO with a molecular weight of 523.4585. Its canonical IUPAC name is 1-[2-[4-[(E)-1-(4-iodophenyl)-2-phenylbut-1-enyl]phenoxy]ethyl]pyrrolidine, and it is also known by several synonyms including 4-iodopyrrolidinotamoxifen and Pyr-I-Tam.

Which organizations have the most patents related to compounds in this chemical space?

The leading patent assignees in this domain are Merck Sharp & Dohme LLC with 1469 patents, Celgene Corp with 838 patents, and Merck Patent GmbH with 744 patents. Other major assignees include Merck and Co Inc, Genentech Inc, Pharmacyclics LLC, Bristol Myers Squibb Co, AstraZeneca AB, F Hoffmann La Roche AG, and Organon Pharma UK Ltd.

What are the key research topics associated with Idoxifene studies?

Published research on Idoxifene covers three main topics: estrogen and related hormone effects, genomics and phytochemicals with oxidative stress considerations, and microtubule and mitosis dynamics. A notable highly-cited paper demonstrates that Idoxifene acts as a selective estrogen receptor modulator, preventing bone loss and lowering cholesterol in ovariectomized rats while decreasing uterine weight in intact rats.

What are the main patent classification areas for chemistry and pharmaceuticals in this field?

The most prevalent patent classifications are A61P (medicinal preparations for treating specific conditions, 16943 patents) and A61K (pharmaceutical preparations, 13908 patents), followed by C07D (heterocyclic compounds, 9982 patents) and C07K (peptides and proteins, 3851 patents). Other significant classifications include C12N, G01N, Y02A, C07C, C12Q, and C07F.

What analytical methods have been developed for detecting Idoxifene in biological samples?

Recent analytical research has focused on high-throughput bioanalytical methods for Idoxifene detection. A 2000 publication described bioanalytical high-throughput selected reaction monitoring-LC/MS determination of estrogen receptor modulators including Idoxifene in human plasma at throughput rates of 2000 samples per day. A 2002 paper detailed atmospheric pressure photoionization liquid chromatographic-mass spectrometric determination of Idoxifene and its metabolites in human plasma.